Literature DB >> 7953267

Sequelae of radical prostatectomy.

M Jønler1, E M Messing, P R Rhodes, R C Bruskewitz.   

Abstract

OBJECTIVE: To evaluate the sequelae of radical prostatectomy, using a survey instrument. PATIENTS AND METHODS: Ninety-three consecutively treated patients who had undergone radical prostatectomy and who had been followed-up for between 12 and 48 months (mean 22.5) were sent a questionnaire by post. Of these, 86 (92%) completed and returned the questionnaire. The mean age of the patients at time of surgery was 64 years (range 49-75) and at time of follow-up was 66 years (range 50-77).
RESULTS: Of the 86 patients who responded, 47% used a pad and 59% leaked urine daily. Thirty per cent dripped more than a few drops of urine daily and 34% found their incontinence bothersome. Eighty-four per cent of patients recalled that they had erectile potency before surgery. At follow-up, 9% were able to have a full erection and 38% were able to have a partial erection. Fifty-one per cent reported a substantial problem with reduced or absent erection. Twenty per cent had undergone treatment for bladder neck contracture and more than half of these had had more than one intervention. In all, 24% of the patients reported some persisting degree of physical unpleasantness which they believed to be secondary to their prostate cancer or the effects of treatment. Despite this, 74% were satisfied with their surgery and 88% said they would undergo surgery again.
CONCLUSIONS: Using this survey instrument, we found adverse sequelae of radical prostatectomy to be surprisingly high. However, patients were generally satisfied with their decision to undergo surgery.

Entities:  

Mesh:

Year:  1994        PMID: 7953267     DOI: 10.1111/j.1464-410x.1994.tb16626.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  11 in total

Review 1.  Prostate cancer: 6. Surgical treatment of localized disease.

Authors:  S L Goldenberg; E W Ramsey; M A Jewett
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

2.  Prostate cancer: 8. Urinary incontinence and erectile dysfunction.

Authors:  M M Hassouna; J P Heaton
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

Review 3.  Localized prostate cancer: early intervention or expectant therapy?

Authors:  T R Griffiths; D E Neal
Journal:  J R Soc Med       Date:  1997-12       Impact factor: 5.344

4.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

5.  Therapeutic strategies for localized prostate cancer.

Authors:  J H Lynch; J T Batuello; E D Crawford; L G Gomella; J Kaufman; D P Petrylak; A B Joel
Journal:  Rev Urol       Date:  2001

Review 6.  The current and potential role of cryoablation as a primary therapy for localized prostate cancer.

Authors:  Aaron E Katz; John C Rewcastle
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

7.  Assessment of the continence status and patients' satisfaction after retropubic radical prostatectomy: a questionnaire based study.

Authors:  Oktay Demirkesen; Bulent Onal; Burcin Tunc; Bulent Alici; Ali Ulvi Onder; Ali Ugur Ozalp; Bulent Cetinel
Journal:  Int Urol Nephrol       Date:  2006-09-28       Impact factor: 2.370

8.  Bulbocavernosus reflex testing: a preliminary study on the prognostic factors for potency and response to sildenafil citrate after bilateral nerve-sparing radical prostatectomy.

Authors:  Shai Shefi; Manuel Zwecker; Jehonathan H Pinthus; Yoram Mor; Gabriel Zeilig; Yeheskell Shemesh; Jacob I Hanani; Gil Raviv
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

Review 9.  Does the CaverMap device help preserve potency?

Authors:  H L Kim; D A Mhoon; C B Brendler
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

10.  Waning sexual function--the most important disease-specific distress for patients with prostate cancer.

Authors:  A R Helgason; J Adolfsson; P Dickman; M Fredrikson; S Arver; G Steineck
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.